Cynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says

MT Newswires Live

Feb 12

Cynata Therapeutics' (ASX:CYP) lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's (ASX:MSB) Ryoncil sets a high market precedent, according to a Feb.10 note by Euroz Hartleys.

Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.

Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell (MSC) therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.

Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.

It maintained CYP's speculative buy rating and $0.67 price target.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510694533"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510694533\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510694533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 07:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510694533","market":"us","top_or_hot":-1,"title":"Cynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> Cynata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (ASX:CYP) lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's (ASX:MSB) Ryoncil sets a high market precedent, according to a Feb.10 note by <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.</p><p>Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell (<a href=\"https://laohu8.com/S/NPW.SI\">MSC</a>) therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.</p><p>Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.</p><p>It maintained CYP's speculative buy rating and $0.67 price target.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-12 07:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Cynata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (ASX:CYP) lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's (ASX:MSB) Ryoncil sets a high market precedent, according to a Feb.10 note by <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.</p><p>Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell (<a href=\"https://laohu8.com/S/NPW.SI\">MSC</a>) therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.</p><p>Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.</p><p>It maintained CYP's speculative buy rating and $0.67 price target.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4575","symbol_name":"芯片概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510694533","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510694533","pubTimestamp":1739315479,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cynata Therapeutics'  lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's  Ryoncil sets a high market precedent, according to a Feb.10 note by Euroz Hartleys.Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell  therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.It maintained CYP's speculative buy rating and $0.67 price target.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4575":"芯片概念","BK7501":"新冠治疗股","CYP.AU":"CYNATA THERAPEUTICS LTD","BK4150":"赌场与赌博","MSC":"新濠影汇","BK4139":"生物科技","MSB.AU":"MESOBLAST LTD","MESO":"Mesoblast Limited","BK7067":"生物科技","BK7508":"医药生物股","LENZ":"Therapeutics"},"translate_title":"Euroz Hartleys表示，在Mesoblast推出Ryoncil后，Cynata Therapeutics的候选药物可能会出现定价调整","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYP.AU":0.9,"LENZ":1,"MESO":1,"MSB.AU":1,"MSC":1},"content_text":"Cynata Therapeutics' (ASX:CYP) lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's (ASX:MSB) Ryoncil sets a high market precedent, according to a Feb.10 note by Euroz Hartleys.Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell (MSC) therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.It maintained CYP's speculative buy rating and $0.67 price target.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}